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Enhanced Survival Associated with Vitiligo Expression
during Maintenance Biotherapy for Metastatic
Melanoma
Peter D. Boasberg1, Dave S.B. Hoon2, Lawrence D. Piro1, Maureen A. Martin1, Akhide Fujimoto2,
Timothy S. Kristedja1, Sandeep Bhachu1, Xing Ye2, Regina R. Deck1 and Steven J. O’Day1
Vitiligo, an autoimmune skin disorder, was evaluated in 49 metastatic melanoma patients treated with an
immunotherapy regimen of maintenance biotherapy (mBT) following induction concurrent biochemotherapy
(cBCT). Patients receiving mBT demonstrated a stable or better response to cBCT. The mBT regimen consisted of
outpatient subcutaneous injections of low-dose IL-2 (1 MIU/m2) 5/7 days weekly, GM-CSF (125 mcg/m2) 14 days
monthly, and high-dose pulses of in-patient continuous infusion decrescendo IL-2 (54 MIU/m2) over 48 hours
monthly for the first 6 months and every 2 months thereafter. The majority of patients had poor prognostic
features. Forty-nine patients were without evidence of vitiligo at the start of mBT. Of these, 21 patients (43%)
developed vitiligo during mBT and had a median overall survival from the start of mBT of 18.2 months (95% CI,
12.3-N/A) compared to 8.5 months (95%CI o6.7–12.7) for 28 non-vitiligo patients (P¼ 0.027). Six of 21 vitiligo
patients (29%) expressed IgG antibody titers to tyrosinase-related protein-2 compared to four of 28 non-vitiligo
patients (14%) (P¼NS). The development of vitiligo in metastatic melanoma patients on cBCT/mBT
immunotherapy correlates with a better therapeutic outcome.
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INTRODUCTION
Vitiligo is an autoimmune depigmenting disorder of the skin,
characterized by the appearance of white patches owing to
loss of epidermal melanocytes and is frequently observed in
association with other autoimmune diseases, such as auto-
immune thyroiditis, lupus erythematosus, and insulin-depen-
dent diabetes mellitus (Kemp et al., 2001; Ongenae et al.,
2003). The immune pathogenic processes involved in the
destruction of melanocytes in vitiligo are still unknown
(Buendia-Eisman et al., 1997; Ongenae et al., 2003);
however, the presence of specific melanocyte antibodies
(Ongenae et al., 2003), elevated peripheral blood anti-
melanocytic T cells, and perilesional immunohistochemical
studies (Ongenae et al., 2003) support the autoimmune
nature of vitiligo (Ogg et al., 1998; Das et al., 2001).
Vitiligo expression has been observed in malignant
melanoma patients by several investigators (Schallreuter
et al., 1991), although the incidence and significance vary
widely (Buendia-Eisman et al., 1997). This association may
be considered to be a result of a targeted immune response to
melanoma-associated antigens (MAAs) shared by normal
melanocytes and melanoma cells (Schallreuter et al., 1991;
Buendia-Eisman et al., 1997) and may reflect autoimmunity
triggered by a response to melanoma, which in turn leads to
the regression of melanoma (Buendia-Eisman et al., 1997).
Common MAAs that are expressed frequently in cutaneous
melanomas and are immunogenic in humans include MART-
1, TRP-1, tyrosinase-related protein-2 (TRP-2), tyrosinase, and
gp100 (Huang et al., 1998; Takeuchi et al., 2004). Previous
studies have suggested that vitiligo is associated with an
improved prognosis for all stages of melanoma patients
(Norlund et al., 1983; Bystryn et al., 1987). Clinical trials of
immune-based therapies in metastatic melanoma have
correlated vitiligo with an improved clinical response,
implicating an immune-modulating effect against metastatic
disease (Richards et al., 1992; Rosenberg and White, 1996;
Phan et al., 2001; Gogas et al., 2006).
In this report, we studied 49 metastatic melanoma patients
treated with a novel maintenance biotherapy (mBT) regimen
of IL-2 and GM-CSF following remission induction with
concurrent biochemotherapy (cBCT) (dacarbazine, cisplatin,
vinblastine, IL-2, and IFN alpha-2b and evaluated the
subjects’ development of vitiligo over the treatment period.
RESULTS
Patient characteristics
Of the 54 patients enrolled to receive mBT, 49 patients were
without evidence of vitiligo at the start of treatment. Five
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patients had documented vitiligo upon completion of cBCT
and were excluded from further analysis. Of the 49 patients,
34 (69%) patients were male and 15 (31%) were female. Ages
ranged from 17 to 70 years (median, 48 years). Twenty-one
(43%) patients had an Eastern Cooperative Oncology Group
score of 0; 22 (45%) had an Eastern Cooperative Oncology
Group score of 1; and six (12%) had an Eastern Cooperative
Oncology Group score of 2. One (2%) patient had stage M1a;
13 (27%) had M1b; and 35 (71%) had M1c disease. Twenty
(41%) patients had lactate dehydrogenase 4190 IU/L (Tables
1 and 2).
RESPONSE
All patients achieved a response of stable or better to cBCT
before the initiation of mBT. Twenty-one patients (43%) had a
complete remission to cBCT alone or after surgical resection
of residual metastatic sites. Sixteen patients (33%) had a
partial response, and 12 (24%) patients had stable disease.
Vitiligo was noted in 21 of 49 (43%) patients following the
initiation of mBT (Table 3). Time to onset of vitiligo ranged
between 24 and 202 days (median 35 days) from the start of
mBT. The 21 patients who developed vitiligo had a median
survival from the start of mBT of 18.2 months compared to
8.5 months for the 28 non-vitiligo patients (Table 4) (Figure 1).
Median follow-up for all patients was 12.3 months.
Univariate analysis using vitiligo as a non-time-dependent
covariate demonstrated serum lactate dehydrogenase and
vitiligo as significant predictors for overall survival, whereas
vitiligo was not a significant predictor when used as a time-
dependent covariate. Sites of metastatic disease and the
response to cBCT and performance status were not signifi-
cantly associated with survival (Table 5). Multivariate
analysis demonstrated vitiligo alone was predictive for
improved survival with mBT (Table 6). In the multivariate
analysis, vitiligo as a time-dependent covariate was not a
statistically significant predictor of survival (Tables 4 and 6).
Assessment of anti-TRP-2 antibodies
Patients with and without vitiligo entered into the study were
assessed for anti-TRP-2 antibody responses. Previously, we
demonstrated elevation of anti-TRP-2 IgG responses in
patients receiving active-specific immunotherapy (Okamoto
et al., 1998). An ELISA for anti-TRP-2 was developed for
assessment of human IgG antibody responses as described
previously using recombinant human TRP-2 (Fujii et al.,
2000). This humoral response was used as a surrogate of
autoimmunity to TRP-2. Patients serum were titered as
described in the Materials and methods. Serum obtained
after cBCT treatment and before mBT was assessed retro-
spectively at the same time in all patients with or without
vitiligo. The study involved available serum from vitiligo
patients (n¼21) and non-vitiligo patients (n¼28). Higher
Table 1. Maintenance biotherapy regimen
Schedule Agent Dose Frequency Route Days of cycle
Outpatient schedule IL-2 1 MIU/m2 Monday–Friday s.c. Days 1–29 or Days 3–28 during pulse schedule
GM-CSF 125 mg/m2 Daily s.c. Days 1–14 or Days 3–17 during pulse schedule
In-patient pulse schedule Total 54 MIU/m2
18 MIU/m2 1st 6 h CIV
IL-2 18 MIU/m2 Next 12 h CIV Days 1 and 2
18 MIU/m2 Next 24 h CIV
CIV, continuous intravenous infusion; s.c., subcutaneous.
Table 2. Patient characteristics
All patients (N=49) Vitiligo (N=21) Non-vitiligo (N=28)
M/F
34 (69%)/15 (31%) 15 (71%)/6 (29%) 19 (68%)/9 (32%)
Age median
48 (17–70) 48 (19–66) 45 (17–70)
ECOG
0 21 (43%) 11 (52%) 10 (36%)
1 22 (45%) 8 (38%) 14 (50%)
2 6 (12%) 2 (10%) 4 (14%)
Stage
M1a 1 (2%) 0 (0%) 1 (4%)
M1b 13 (27%) 7 (33%) 6 (21%)
M1c 35 (71%) 14 (67%) 21 (75%)
LHD 4190IL/L 20 (41%) 8 (38%) 12 (43%)
ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase.
Table 3. Response to induction concurrent
biochemotherapy
Patient
Complete
response
Partial
response
Stable
disease
Vitiligo 11 4 6
Non-vitiligo 10 12 6
Total 21 16 12
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incidence of positive anti-TRP-2 IgG titer patients for the
vitiligo patients (six of 21 patients; 29%) compared to the
non-vitiligo patients (four of 28 patients; 14%) was demon-
strated. The studies suggest that anti-TRP-2 antibody produc-
tion may be found more frequently in those patients with
vitiligo versus those patients without. However, the number
of patients overall with positive titers was small and no
statistical difference between the two groups was found. As
described previously, melanoma patients have been shown to
elicit anti-TRP2 antibody responses. Anti-GP100 IgG anti-
body was assessed by affinity ELISA as described previously
(Fujii et al., 2000); however, there was no difference between
vitiligo and non-vitiligo patients (data not shown).
DISCUSSION
In vitiligo, pigment is lost due to reduced epidermal
melanocytes accompanied by a T-cell infiltration of the skin
(Le Poole et al., 2004). The expansion of these infiltrating
lymphocytes in patients with melanoma-associated vitiligo
demonstrates primarily CD-8þ cells. These vitiligo-infiltrat-
ing lymphocytes have a clonal or oligoclonal receptor profile
and recognize differentiation antigens shared by normal
melanocytes and malignant melanoma cells (Le Gal et al.,
2001). Humoral immunity has also been demonstrated in
vitiligo with the MAAs tyrosinase, gp 100, TRP-1, and TRP-2
most commonly eliciting an autoantibody response (Okamo-
to et al., 1998; Ongenae et al., 2003). Vitiligo is therefore
thought to represent a sensitization of the patient to MAAs
resulting in depigmentation (Richards et al., 1992). Both
cellular and humoral immune responses to MAAs have
therefore been observed in vitiligo patients (Richards et al.,
1992). These autoimmune responses are often more en-
hanced in patients with melanoma (Huang et al., 1998; Fujii
et al., 2000; Phan et al., 2001). The anti-TRP-2 responses
observed in our study may represent the patient population
that immune tolerance to TRP-2 has broken down. The higher
frequency in vitiligo patients suggests that this may be one of
many other MAAs where immune tolerance breakdown is
occurring and vitiligo is a surrogate of this event.
Malignant melanoma-associated vitiligo has been reported
by several investigators over the past 30 years (Schallreuter
et al., 1991). Vitiligo has also long been associated with an
improved prognosis in melanoma patients of all disease
stages (Bystryn et al., 1987; Rodriguez-Cuevas et al., 1998).
In studies of immune-based therapies, the development of
vitiligo has been associated with an improved therapeutic
result (Rosenberg and White, 1996; Gogas et al., 2006).
Rosenberg and White (1996) prospectively evaluated
metastasic melanoma patients treated with high dose IL-2 for
the development of vitiligo. Vitiligo was reported in 11 of 74
(15%) melanoma patients. Vitiligo was not observed in 27
patients unresponsive to IL-2 immunotherapy, whereas 11 of
43 (26%) of responding patients developed vitiligo. In a follow-
up paper, 84 of 374 (23%) melanoma patients treated with
high-dose IL-2 developed vitiligo with 33% of the vitiligo
patients responding to the immunotherapy (Phan et al.,
2001). In a study of autologous antitumor T-cell transfer and
high dose IL-2 after non-myeloablative lymphocyte-depleting
chemotherapy, vitiligo developed in two of six responding
patients (Dudley et al., 2002). Gogas et al. (2006) reported
increased overall survival in stage IIB, IIC, and III melanoma
patients receiving adjuvant IFN alpha-2b who developed
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Figure 1. Overall survival between vitiligo and non-vitiligo patients.
Table 5. Univariate analysis – survival
Predictor P-value Hazard ratio (95% CI)
ECOG performance status 0.9114 1.028 (0.633–1.670)
M1a/m 1b vs mlc 0.2433 0.651 (0.317–1.339)
LDH (4190 vs p190) 0.0290 2.729 (1.108–6.722)
CR vs PR/SD 0.4460 0.737 (0.336–1.617)
Developed vitiligo? Yes vs No
Non-time dependent 0.0304 0.483 (0.249–0.993)
Time-dependent 0.0702 0.534 (0.271–1.053)
CI, confidence interval; CR, complete remision; ECOG, Eastern Coopera-
tive Oncology Group; LDH, lactate dehyrogenase; PR, partial remission;
SD, sable disease.
Table 4. Overall survival
Predictor Death/N
Median survival
(95% CI) (months)
Vitiligo none 25/28 8.5 (6.7, 12.7)
Vitiligo developed on study 13/21 18.2 (12.3,/)*
CI, confidence interval.
*P=0.0269 log-rank test per overall survival.
Table 6. Multivariate analysis – survival1
Predictor P-value Hazard ratio (95% CI)
Vitiligo vs non-vitiligo
Non-time dependent 0.0399 0.495 (0.254–0.968)
Time dependent 0.0913 0.552 (0.276–1.100)
1M1a/M1b vs M1c, LDH (4190 vs o190), CR vs PR/SD, vitiligo vs non-
vitiligo, ECOG.
CI, confidence interval.
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multiple manifestations of autoimmunity including anti-
thyroid antibodies, antinuclear antibodies, anticardiolipin
antibodies, and vitiligo. The correlation of autoimmune
phenomena and response has also been reported in meta-
static melanoma patients treated with anti-cytotoxic T-
lymphocyte antigen 4 (CTLA-4) antibodies (Phan et al.,
2003). In many immunotherapy protocols, specific or
nonspecific methods of activation of host immune responses
to MAAs are being targeted. Often strong autoimmune
responses to these MAAs are desired. However, the
consequence is that if truly a high effective immune response
to MAAs is generated it should coincide with autoimmunity.
Although anti-MAA immunity may control metastatic mela-
noma, it is not the only factor responsible for the disease
outcome. We now know that melanoma cells have various
mechanisms to escape host immune responses and proliferate
faster than host-induced tumor cell destruction. Therefore,
the level of autoimmunity generated during therapy may be a
small window showing a visible ongoing physiological event
of host tumor immunity.
In our sequential cBCT/mBT treatment program, the
metastatic melanoma patients who developed vitiligo de-
monstrated a survival benefit over the non-vitiligo patients of
18.2 vs 8.5 months. All patients initially received induction
cBT. The patients who achieved a stable or better response to
cBT were subsequently treated on the mBT program with
high-dose pulses of decrescendo IL-2, low-dose IL-2, and
GM-CSF (O’Day et al., 2002). The strategy of mBT was to
stimulate the proliferation and activation of antigen-present-
ing cells such as dendritic cells and macrophages and to
activate cytotoxic T and helper T cells directed at MAAs
(O’Day et al., 2002). Autoimmune phenomena consisting of
thyroid dysfunction, thrombocytopenia, and vitiligo were
observed on mBT (O’Day et al., 2002). The rapid onset of
vitiligo after the initiation of mBT (median time to develop-
ment of 35 days) is more indicative of an immune response
than simply a consequence of prolonged exposure to IL-2. For
patient survival, univariate and multivariate analysis confirm
the development of vitiligo as significant over other important
prognostic variables, such as sites of metastatic disease,
lactate dehydrogenase levels, performance status, and
response to biochemotherapy. Vitiligo as a time-dependent
covariate was not significant but suggested a significant trend
as a survival predictor.
It is our hypothesis that similar immune mechanisms
documented in patients who develop benign vitiligo also
occur in metastatic melanoma patients with vitiligo. The
combination of humoral and cell-immune-mediated re-
sponses to MAAs shared by normal melanocytes and
melanoma cells results in the expression of vitiligo as well
as potential control of malignant melanoma. The unique
pairing of induction biochemotherapy followed by an
extended mBT program prolongs the stimulation of immune
response mediators manifesting as vitiligo and resulting in a
subsequent survival benefit. In metastatic melanoma patients
receiving mBT, we demonstrated that 20% (10 of 49) of
patients had a positive anti-TRP-2 antibody titer. There was a
trend observed; however, there was no statistical difference
between vitiligo and non-vitiligo patients. These preliminary
studies suggest that anti-TRP-2 antibody can be found during
vitiligo as described previously for active-specific immuno-
therapy (Okamoto et al., 1998). The role of anti-TRP2
antibody is not known but may be a surrogate indicator of
uncontrolled autoimmunity induction to MAAs. Breakdown
of immune tolerance to multiple MAAs may be required to
induce vitiligo. It is not certain whether the responses play a
role in inducing or is an effect of normal cell destruction.
Nevertheless, mBT patients produce an anti-MAA response
that activates autoimmunity at some level. Further studies
are needed in a larger trial to determine the role of anti-TRP-2
with vitiligo and autoimmunity to other MAAs. We assessed
only TRP-2 in this study because previous studies have
shown it to be most prominent in patients with vitiligo. Other
anti-MAA may be involved collectively in vitiligo-melanoma-
associated autoimmune responses. In metastatic melanoma,
vitiligo serves as a potential surrogate marker for an active
immunity to MAAs and correlates with an increased
immune response and an improved patient survival on a
cBT/mBT program. Given its early development (median
time 35 days), vitiligo may be an early indicator of efficacy
helping us to better apply therapy to patients most likely to
benefit.
MATERIALS AND METHODS
Patients
The study population consisted of 49 AJCC stage IV melanoma
patients who received mBT with IL-2 and GM-CSF between May
1998 and November 2000 following induction cBCT (O’Day et al.,
2002). All patients required a response of stable disease or better to
the induction biochemotherapy before proceeding to mBT. Addi-
tional eligibility criteria included age at least 18 years, adequate
organ function defined by a bilirubin o2.0 mg/dl, serum creatinine
o2.5 mg/dl, WBC 42,000/mm3, platelets 450,000/mm3, and an
Eastern Cooperative Oncology Group performance status of 0–2.
Patients with untreated or active central nervous system metastases
were not eligible for study inclusion. However, those with small,
solitary, or limited central nervous system disease treated with
stereotatic radiosurgery or craniotomy were included. Patients
requiring systemic corticosteroid therapy for any reason were
excluded. All patients signed an approved informed consent before
treatment. Protocol was approved by The Saint Johns’ Health Center
and John Wayne Cancer Institute Institutional Review Board, and
was conducted according to the Declaration of Helsinki Principles.
Treatment regimen
Patients initially received in-patient treatment with intravenous
DTIC, cis-platinum and vinblastine, subcutaneous alpha-IFN, and a
continuous intravenous infusion of IL-2 with descrescendo dosing.
Each patient was evaluated for response after two cycles of cBCT. No
patient received more than six treatment cycles of cBCT. mBT began
4 weeks after the first day of the qualifying patients last cycle of
cBCT.
mBT (Table 1) consisted of 28-day cycles of outpatient low-dose
IL-2 (Proleukins, Chiron Corporation, Emeryville, CA) at 1 MIU/m2/
day delivered by daily subcutaneous injection (Monday–Friday), and
GM-CSF (Leukines, Berlex Laboratories Inc., Montville, NJ) at
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125 mcg/m2/day by daily subcutaneous injection on days 1–14 of
each cycle. Intermittent pulses of high dose decrescendo IL-2
preceded the low-dose regimen on days 1 and 2 of cycles 2, 3, 5, 6,
8, 10, and 12. The high-dose IL-2 was administered in the hospital at
18 MIU/m2 by continuous intravenous infusion over the first 6 hours,
18 MIU/m2 over the next 12 hours, and 18 MIU/m2 over the next
24 hours. The outpatient IL-2/GM-CSF regimen followed the in-
patient pulses of IL-2 for the remainder of the 28-day cycle (O’Day
et al., 2002). Induction of cBCT without Tamoxifen was adminis-
tered as outlined in a previous report (O’Day et al., 1999).
Response evaluation
Patients were evaluated by physical examination at each in-patient
treatment cycle for the presence or absence of hypopigmentation.
The development of new areas of hypopigmentation on the arms,
legs, or torso was considered vitiligo. The vitiligo was not graded by
sites, single or multiple, size, or location. Before the start of mBT and
after three 28-day cycles, patients were evaluated with computer-
ized tomography of the chest, abdomen, and pelvis and magnetic
resonance imaging of the brain. Patients were allowed to receive
additional cycles of mBT, if minor progression occurred without an
accompanying deterioration in their performance status (O’Day
et al., 2002).
Anti-TRP-2 ELISA
TRP-2 was cloned from a human melanoma cell line and expressed
in E. coli BL21 cells as described previously (Tanaka et al., 2002).
Recombinant TRP-2 protein was purified by affinity chromatography
and then subjected to endotoxin removal. An affinity IgG ELISA was
performed with recombinant TRP-2 protein as described previously
in 96-well ELISA microtiter plates (Fujii et al., 2000).
Melanoma patients had their blood drawn after completion of the
cBCT regimen, before and at three and six months after the start of
mBT. Blood collection, serum processing, and cryopreservation was
as described previously (Huang et al., 1998). Cryopreserved cBCT
patient sera was thawed and assessed at serial dilutions of 1:200 to
1:64,000 in duplicates to obtain the highest positive antibody titer to
TRP-2. All assay results were obtained as absorbance at 490 nm.
A negative control pool (n¼ 5) of normal healthy donors sera was
used as negative control background. Previously, we have
shown normal healthy donors (n¼ 21) do not have a significant
positive antibody titer to TRP-2 (Okamoto et al., 1998). Serum with a
mean absorbance reading greater than two standard deviations
above the pooled negative controls were considered as a positive
IgG titer. Results were expressed as the highest anti-TRP-2 IgG titer
for each serum sample. Overall, a significant positive antibody
titer was considered when the anti-TRP-2 IgG titer was greater
than 1:200.
Statistics
Overall survival was estimated according to the Kaplan–Meier
method and defined as the period from day one of mBT to date of
death or last follow-up. Comparison of survival was done using the
log-rank test. Univariate and multivariate analysis of overall survival
was performed using a Cox proportional hazards regression model of
clinically important prognostic features, including visceral versus
non-visceral sites of metastases (M1a/M1b vs. M1c), the laboratory
upper limit of normal serum lactate dehydrogenase (4190 IU/L vs.
o190), response to cBCT (complete remission vs partial response or
stable disease), Eastern Cooperative Oncology Group performance
status, and the development of vitiligo. Vitiligo was evaluated as
both a time-dependent and non-time-dependent. Covariate stepwise
procedure was used for covariate selection.
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